Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Andrew Scott Paulson"'
Autor:
Lipika Goyal, Smitha Krishnamurthi, Dung T Le, Ronan J Kelly, Cathy Eng, Geoffrey Ku, Manish A Shah, Marwan Fakih, Joseph Chao, Van K Morris, Katherine Bever, Kristen K Ciombor, Joleen Hubbard, Renuka Iyer, Holly T Kemberling, Mindy Mintz Mordecai, Andrew Scott Paulson, Valerie Peterson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a signific
Externí odkaz:
https://doaj.org/article/ebebf3bf4cc94f57adb8f23cda6cee23
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Arvind Dasari, Erika P. Hamilton, Gerald S. Falchook, Judy S. Wang, Daneng Li, Max W. Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson
Publikováno v:
Investigational New Drugs.
Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddcb9a02f4a998a162d10207c8e45627
https://doi.org/10.1007/s10637-023-01359-2
https://doi.org/10.1007/s10637-023-01359-2
Autor:
Zev A. Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle De La Fouchardiere, Andrew Peter Dean, Igor Kiss, Woojin Lee, Thorsten Oliver Goetze, Eric Van Cutsem, Andrew Scott Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Richard Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen Mary O'Reilly
Publikováno v:
Journal of Clinical Oncology. 41:LBA661-LBA661
LBA661 Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for mPDAC following progression with gemcitabine-based therapy. A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adedb988a055c95df9b251d7f4a27304
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
Autor:
Andrea Cercek, Kimmie Ng, John H Strickler, Salvatore Siena, Thierry Andre, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz-Josef Lenz, Kristen Keon Ciombor, Elena Elez, Michael Stecher, Pauline Cronin, Wentao Feng, Tanios S. Bekaii-Saab
Publikováno v:
Journal of Clinical Oncology. 41:198-198
198 Background: HER2 overexpression/amplification (HER2+) occurs in 3%-5% of patients (pts) w/ metastatic colorectal cancer (mCRC). Rates of HER2+ can increase to ~10% in pts w/ RAS/BRAF wild-type mCRC tumors. The MOUNTAINEER trial (NCT03043313) eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7cb4ac04391fe9cdde110dd59a0096f
https://doi.org/10.1200/jco.2023.41.4_suppl.198
https://doi.org/10.1200/jco.2023.41.4_suppl.198
Autor:
Luis Féliz, Efrat Dotan, Arndt Vogel, Christine F. Lihou, Antoine Hollebecque, Kristen Bibeau, Daniel Virgil Thomas Catenacci, Ghassan K. Abou-Alfa, E. Van Cutsem, Davide Melisi, Andrew Scott Paulson, Mitesh J. Borad, Gina M. Vaccaro, David Gallinson, Raed Al-Rajabi, D-Y. Oh, Vaibhav Sahai, Haobo Ren, Adrian Murphy
Publikováno v:
Annals of Oncology. 32:S203-S204
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc885617aa338863e8629d552ec75ca9
https://doi.org/10.1016/j.annonc.2021.05.028
https://doi.org/10.1016/j.annonc.2021.05.028
Autor:
Lola Rahib, David Kuang-Fu Chang, Davendra Sohal, Conan Grant Kinsey, Deborah Christensen, Mark Shapiro, Fatima Zelada-Arenas, Andrew Scott Paulson, Muhammad Shaalan Beg
Publikováno v:
Journal of Clinical Oncology. 40:527-527
527 Background: We initiated a nationwide Virtual Tumor Board (VTB) program for pancreatic cancer (PC) patients (pts). The VTB consists of oncology experts and serves as an advisory panel by providing information on treatment (Tx) options based on a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d9eb106e40471ad86ef03347024ade6
https://doi.org/10.1200/jco.2022.40.4_suppl.527
https://doi.org/10.1200/jco.2022.40.4_suppl.527
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Timothy Larson, Allen Lee Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, David R. D'Adamo, Amy Hammell, Neelesh Sharma, Sabine Coppieters, Anke Schulz, Henrik Seidel, Matthias Herpers, Carolina Soares Viana de Oliveira, Andrew Scott Paulson, Ying A. Wang
Publikováno v:
Journal of Clinical Oncology. 40:89-89
89 Background: Combination treatment with regorafenib (80–120 mg/day, PO, 3 wks on/1 wk off) plus nivolumab (480 mg IV Q4W) showed manageable safety but modest efficacy in a phase 2 study of 70 pts from North America with pMMR/MSS chemotherapy-resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e6d2629f340091b5aa3e06f2b9d906c
https://doi.org/10.1200/jco.2022.40.4_suppl.089
https://doi.org/10.1200/jco.2022.40.4_suppl.089
Autor:
Gontran Verset, James Lee, Sadahisa Ogasawara, Suresh Ratnam, Vittorina Zagonel, Angela Tatiana Alistar, Scot Ebbinghaus, Robin Kate Kelley, Chris Verslype, Daniel H. Palmer, Masatoshi Kudo, Olivier Rosmorduc, Ivan Borbath, Alan Weiss, Atisha Manhas, Carmine Pinto, Yutaka Sasaki, Yvonne Sada, Bruno Daniele, Laetitia Fartoux, Karl-Heinz Weiss, Daneng Li, Andrea L. Webber, Timothy Cannon, Gina M. Vaccaro, Per I Stal, Timothy Larson, Mukul Gupta, Jean-Frédéric Blanc, Simone I. Strasser, Kazushi Numata, Tatsuya Yamashita, David Cosgrove, Allen Lee Cohn, Ki Chung, Junshui Ma, Julien Edeline, Yoshivasu Karino, Jennifer J. Knox, Joerg Trojan, Debashis Sarker, Nevena Damjanov, Hans Van Vlierberghe, Richard S. Finn, Stephen L. Chan, Andreas Kaubisch, Jamil Asselah, Andrew X. Zhu, Magnus Rizell, Jena-Luc Van Laethem, Robert A. Ramirez, Mark Karwal, Gulam Abbas Manji, Ann-Lii Cheng, Arndt Vogel, Andrew Scott Paulson, Stéphane Cattan, Abby B. Siegel, Benjamin M. Parsons
Publikováno v:
The Lancet Oncology. 19:940-952
Summary Background Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Methods KEYNOTE-224 is a non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d63031639b53d0c366d883aa6d97a8e
https://doi.org/10.1016/s1470-2045(18)30351-6
https://doi.org/10.1016/s1470-2045(18)30351-6
Autor:
David Gallinson, Arndt Vogel, Adrian Murphy, Tao Ji, Davide Melisi, Hui-Ling Zhen, Christine F. Lihou, Daniel V.T. Catenacci, Vaibhav Sahai, Eric Van Cutsem, Luis Féliz, Ghassan K. Abou-Alfa, Do-Youn Oh, Efrat Dotan, A. Hollebecque, Gina M. Vaccaro, Andrew Scott Paulson, Mitesh J. Borad, Raed Al-Rajabi
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea3af0d8a91bc2a0476bb68558fb14d
https://doi.org/10.2139/ssrn.3489302
https://doi.org/10.2139/ssrn.3489302